SB3191 is proposed legislation to amend the Illinois Controlled Substances Act provisions (including 720 ILCS 570/401 and 720 ILCS 570/401.1) by increasing penalties for certain fentanyl-related conduct. As described in the bill materials, it would make unlawfully selling/dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony (with specified imprisonment range and fines), and it would add a separate Class 1 felony for knowingly using an electronic communication device in furtherance of controlled substance trafficking involving fentanyl. The ILGA bill status shows the bill was referred to Senate Assignments on 2/02/2026. Compliance teams should monitor for enactment and prepare for potential updates to controlled-substance compliance programs, training, and risk assessments tied to fentanyl-containing products and communications evidence.
SB3221 (104th GA) proposes amending the Illinois Controlled Substances Act to add xylazine as a Schedule/Class III controlled substance and make related structural/list changes, with stated exemptions for specified veterinary/animal-drug contexts (per research text summary). The bill status page shows the bill was referred to Senate Assignments on 2026-02-02 and includes a proposed effective date of 2027-01-01. If enacted, entities handling xylazine in non-exempt contexts would face new controlled-substance compliance obligations (storage, handling, distribution controls) and potential criminal liability exposure; organizations with veterinary or animal-health operations should review how exemptions would apply to their use cases.
Illinois SB3213 (introduced; not shown as enacted in provided materials) would amend 720 ILCS 570/311.6 to add/clarify exceptions to the requirement that Schedule II–V controlled substance prescriptions be issued electronically, including circumstances such as after-hours access needs and drug shortages/inventory limitations. The bill also proposes changes (in the Pharmacy Practice Act) to align controlled-substance prescription transfer rules with federal requirements (e.g., one-time transfer with an exception for shared real-time databases). Compliance teams for prescribers and pharmacies should monitor for potential workflow and policy changes on when paper/alternative prescribing is permitted and how transfers are handled.
Illinois SB3191 (104th GA) was introduced to amend the Illinois Controlled Substances Act (including provisions tied to 720 ILCS 570/401 and 720 ILCS 570/401.1). As described in the bill text sources, it proposes heightened felony consequences for unlawful selling/dispensing of scheduled drugs containing a detectable amount of fentanyl, and proposes creating an additional offense/penalty for knowingly using an electronic communication device in furtherance of fentanyl-related controlled substance trafficking. Compliance relevance: if enacted, entities involved in controlled substance handling (pharmacies, distributors, healthcare, and compliance/legal teams) would need to account for changed criminal exposure and enforcement posture related to fentanyl-containing products and communications-facilitated trafficking.
The Illinois Compiled Statutes text for 720 ILCS 570/302(c)(3) reflects an update (source note: Public Act 104-336) to explicitly include authorized employees of organizations providing hospice services or home health services among persons who may lawfully possess a controlled substance prescribed for the ultimate user. The ILCS source note indicates an effective date of 2026-01-01. This change affects compliance policies for hospice and home health providers regarding possession, custody, and handling of patient-prescribed controlled substances and may require updates to internal authorization/training documentation and controlled substance handling procedures.
In its Fall 2025 Compliance Capsule newsletter, IDFPR highlights 720 ILCS 570/311.6(e), emphasizing that a pharmacist may not refuse to fill a valid controlled-substance prescription solely because it is not prescribed electronically, and that pharmacists are not responsible for enforcing prescriber compliance with electronic prescribing of controlled substances (EPCS) requirements. This guidance is operationally relevant for pharmacies’ dispensing policies, staff training, and refusal-to-fill procedures, especially where workflows have been configured to reject non-electronic controlled-substance prescriptions.
Public Act 104-0424 amends the Illinois Controlled Substances Act electronic prescribing provisions to extend the period during which prescriptions issued by a licensed veterinarian are not required to be issued electronically. The exemption window is extended to 7 years after November 17, 2023 (extended from a prior 2-year window). Compliance teams supporting veterinary prescribing workflows and e-prescribing controls should update policy logic and exception handling based on the amended exemption period.
Illinois enacted Public Act 104-0424 (SB2469), amending 720 ILCS 570/311.6 (electronic prescribing for Schedule II–V controlled substances). The amendment extends the veterinarian exception to the electronic-prescribing requirement: prescriptions issued by a licensed veterinarian are not required to be electronic within 7 years after November 17, 2023 (previously 2 years). Compliance teams supporting veterinary practices and pharmacies should update EPCS compliance logic, workflows, and policy documentation to reflect the extended transition period for veterinarians under Illinois law.
The ILGA bill status for SB1569 shows the measure (proposing fentanyl-related sentencing enhancement changes under the Illinois Controlled Substances Act) was re-referred to the Senate Assignments committee (Rule 3-9(a)) on 2025-04-11. This is legislative status activity (not enactment). Compliance teams tracking potential changes to fentanyl-related penalty structures should monitor further movement before making policy updates.
Illinois SB1569 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to increase certain fentanyl-related sentencing enhancements, including changing an added sentence from 3 years to 5 years for manufacture/delivery (or possession with intent) when a substance contains any amount of fentanyl. The Illinois General Assembly bill status reflects a legislative action on 2025-04-11: the measure was re-referred to the Senate Assignments committee. Compliance teams should track because it signals ongoing legislative movement on heightened fentanyl penalties that could impact enforcement risk and criminal liability frameworks if enacted.
HB0077 (104th General Assembly) proposes amending the Illinois Controlled Substances Act to schedule xylazine as a Schedule III controlled substance and to establish explicit exemptions for defined lawful activities (e.g., use by licensed veterinarians in professional practice; certain euthanasia technicians; wildlife biologists under veterinary supervision; other specified lawful uses). The bill status page shows last action on 2025-03-21 (re-referred to Rules Committee). If enacted, regulated entities (veterinary practices, suppliers, facilities handling xylazine) would need to implement controlled-substance handling controls unless covered by an exemption.
Public Act 103-1064 (HB 5373) amends the Illinois Controlled Substances Act, including provisions affecting opioid/chronic pain prescribing and the Illinois Prescription Monitoring Program (ILPMP). The amendment states that ordering/prescribing/dispensing/administering/paying for controlled substances (including opioids) must not be predetermined by specific morphine milligram equivalent (MME) guidelines except as provided under federal law. It also tightens/clarifies conditions for release of confidential PMP data, requiring a written showing of a valid court order/subpoena or an administrative subpoena issued by IDFPR, and excludes 42 CFR Part 2–protected records/opioid treatment program confidential information from inter-agency sharing. Compliance teams should review controlled-substance prescribing policies, PMP access/request procedures, and data handling workflows to ensure subpoena/court-order gating and Part 2 segregation are implemented.
Illinois HB2804 (104th GA) proposes amendments to the Illinois Controlled Substances Act to establish or expand Class X felony treatment for certain fentanyl-involved selling/dispensing conduct, add a separate Class 1 felony provision tied to using an electronic communication device in furtherance of fentanyl-related trafficking, and add additional sentencing enhancement concepts based on form/packaging (e.g., product forms resembling consumer candy/branding). Compliance relevance: if enacted, it would increase criminal exposure associated with fentanyl-containing substances and introduce new enhancement triggers that could affect enforcement and compliance risk assessments.
Illinois HB2804 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to create and expand fentanyl/carfentanil-specific offenses and sentencing enhancements. The proposal includes making selling/dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony (with specified sentencing and fine ranges), creating additional penalties for use of electronic communication devices in fentanyl-related trafficking, and adding an additional 5-year sentence when fentanyl is presented in consumer-appealing forms (e.g., candy/gummy-like or similar trade dress). The official bill status shows it was referred to the House Rules Committee on 2025-02-06. Compliance teams should monitor due to potential substantial increases in criminal liability exposure if enacted.
HB2804 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act (including Sections 401 and 401.1 per the bill materials) to create/expand fentanyl-specific criminal provisions. The introduced bill materials describe Class X felony treatment for knowingly/unlawfully selling or dispensing any scheduled drug containing a detectable amount of fentanyl, an additional felony for using an electronic communication device in furtherance of trafficking involving fentanyl, and additional sentencing provisions for specified fentanyl/carfentanil amounts and presentations. The ILGA status page shows last action 2025-02-06 (referred to House Rules Committee).
Illinois HB2931 was introduced (104th General Assembly) and includes amendments affecting the Illinois Controlled Substances Act (720 ILCS 570). Compliance teams should monitor the bill’s progress because, if enacted, it would change statutory obligations/authorities under the ICSA (specific operational impacts depend on the final enacted language and any implementing agency guidance).
SB1773 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act to schedule xylazine as a Class III controlled substance; the bill PDF synopsis states an effective date of 2026-01-01. An amendment document was also identified that adds xylazine exemption language (e.g., circumstances where xylazine would not be considered a controlled substance). Stakeholders should monitor because scheduling would create new controlled-substance compliance obligations for entities handling xylazine unless exempted.
SB1553 (104th General Assembly) proposes amending the Illinois Controlled Substances Act to add xylazine to the Schedule III controlled substances list and to establish additional provisions addressing xylazine (including a veterinarian-related provision described in the introduced bill text, and penalty-related amendments tied to manufacture/delivery/possession-with-intent). If enacted, it would extend controlled-substance compliance obligations to xylazine in Illinois, affecting veterinary supply chains and any entities handling xylazine outside the scope of professional-practice exceptions.
Illinois SB1553 (104th GA) proposes amendments to the Illinois Controlled Substances Act to add xylazine to Schedule III and to create a xylazine/veterinarian carve-out (per introduced text), along with penalty-related amendments (including changes referenced to 720 ILCS 570/401 in the bill text/PDF). Compliance relevance: if enacted, it would add xylazine scheduling obligations and may change penalty structures for certain controlled substance offenses involving xylazine, while clarifying treatment of licensed veterinarians acting in professional practice.
An ILPMP newsletter (Feb 2025) reports that Public Act 103-1064 (effective 2025-02-07) was incorporated into the Illinois Controlled Substances Act and imposes stricter prerequisites for law-enforcement/authorized requestors seeking confidential ILPMP data. The newsletter describes requirements including a reason-to-believe standard, that the request be reasonably related to an investigation, and that a valid court order or subpoena be provided (with limitations described for administrative subpoenas). It also notes the prior online law-enforcement request portal is no longer available. This is compliance-relevant for agencies and entities requesting ILPMP data and for program administrators handling disclosures, as request intake, documentation review, and disclosure procedures must align with the updated statutory requirements.